Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -270.04% is 58% above its 5-year average of -640.04%, near the high end of its 5-year range (-955083.33%–43.71%).
95.12% above its 12-month average of -5531.52%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -24723.06%.
EBITDA MARGIN
-270.04%
EBITDA MARGIN AVG TTM
-5531.52%
EBITDA MARGIN AVG 3Y
-724.62%
EBITDA MARGIN AVG 5Y
-640.04%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+95.12%
CURRENT VS 3Y AVG
+62.73%
CURRENT VS 5Y AVG
+57.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Beam Therapeutics Inc.
Market Cap
$2.52B
EBITDA Margin
-270.04%
TTM Avg
-5531.52%
3Y Avg
-724.62%
5Y Avg
-640.04%
Market Cap
$2.76B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$2.16B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$1.90B
EBITDA Margin
1.74%
TTM Avg
-0.52%
3Y Avg
3.36%
5Y Avg
2.51%
Market Cap
$1.74B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.71B
EBITDA Margin
-628.14%
TTM Avg
-766.74%
3Y Avg
-948.44%
5Y Avg
-801.32%
Market Cap
$1.00B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$474.59M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | $2.52B | -270.04% | -5531.52% | -724.62% | -640.04% |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 22.42% | 17.70% | -0.76% | -37.34% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | -755.79% | -753.93% | -709.93% | -1157.85% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.90B | 1.74% | -0.52% | 3.36% | 2.51% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 16.41% | 1.22% | -1.65% | 4.31% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | -628.14% | -766.74% | -948.44% | -801.32% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 3.96% | -13.21% | -146.19% | -104.68% |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | 0.24% | -1.36% | -6.49% | -5.53% |
| NRC Health (NRC)vs › | $458.62M | 21.99% | 25.40% | 28.98% | 31.97% |
| Shoulder Innovations, Inc. (SI)vs › | $394.23M | -48.80% | -44.09% | -45.35% | -45.35% |
Gross Margin
84.0%
EBITDA Margin
-270.0%
Operating Margin
-274.6%
Net Margin
-54.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -24723.06% |
| 2026-03-31 | -320.15% |
| 2025-12-31 | -10.32% |
| 2025-09-30 | -1250.27% |
| 2025-06-30 | -1353.80% |
| 2025-03-31 | -1522.86% |
| 2024-12-31 | -314.61% |
| 2024-09-30 | -708.03% |
| 2024-06-30 | -843.69% |
| 2024-03-31 | -1332.00% |
| 2023-12-31 | 43.71% |
| 2023-09-30 | -599.55% |
| 2023-06-30 | -483.85% |
| 2023-03-31 | -389.46% |
| 2022-12-31 | -424.42% |
| 2022-09-30 | -555.92% |
| 2022-06-30 | -471.70% |
| 2022-03-31 | -864.72% |
| 2021-12-31 | -119.15% |
| 2021-09-30 | -8896.99% |
| 2021-06-30 | -955083.33% |
| 2021-03-31 | -3316250.00% |
| 2020-12-31 | -658783.33% |
| 2020-09-30 | -601716.67% |
| 2020-06-30 | -419000.00% |
| 2020-03-31 | -454250.00% |
| 2019-12-31 | -422816.67% |
| 2019-09-30 | -285266.67% |
| 2019-06-30 | -279883.33% |
